Champions Oncology, Inc. Q3 2026 Earnings Recap
Champions Oncology reported a strong third quarter, achieving record services revenue and maintaining positive adjusted EBITDA for the third consecutive quarter, despite a slight year-over-year decline in total revenue.
Earnings Per Share
Miss
$-0.02
vs
$0.09 est.
-122.2% surprise
Revenue
Miss
16559000
vs
16613000 est.
-0.3% surprise
Market Reaction
1-Day
+6.27%
5-Day
+1.57%
Key Takeaways
- Core study revenue reached a record $16.6 million, growing approximately 32% year-over-year.
- The company remains on track for full-year revenue growth and positive adjusted EBITDA while investing in data and drug discovery initiatives.
- Early momentum is evident in the data business with new deals closed and revenue expected in the fourth quarter.
- Champions is committed to maintaining disciplined capital allocation while investing for future growth without diluting shares.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit
CSBR on AllInvestView.
Also Reported on March 13, 2026
Get the Full Picture on CSBR
Track Champions Oncology, Inc. in your portfolio with real-time analytics, dividend tracking, and more.
View CSBR Analysis